Optimal path planning method of electric vehicles considering power supply

Because of the limitations of electric vehicle(EV)battery technology and relevant supporting facilities,there is a great risk of breakdown of EVs during driving.The resulting driver“range anxiety”greatly affects the travel quality of EVs.These limitations should be overcome to promote the use of EVs.In this study,a method for travel path planning considering EV power supply was developed.First,based on real-time road conditions,a dynamic energy model of EVs was established considering the driving energy and accessory energy.Second,a multi-objective travel path planning model of EVs was constructed considering the power supply,taking the distance,time,energy,and charging cost as the optimization objectives.Finally,taking the actual traffic network of 15 km×15 km area in a city as the research object,the model was simulated and verified in MATLAB based on Dijkstra shortest path algorithm.The simulation results show that compared with the traditional route planning method,the total distance in the proposed optimal route planning method increased by 1.18%,but the energy consumption,charging cost,and driving time decreased by 11.62%,41.26%and 11.00%,respectively,thus effectively reducing the travel cost of EVs and improving the driving quality of EVs.

乙酰唑胺治疗慢性高原病的疗效与安全性的Meta分析

目的系统评价乙酰唑胺(ACZ)治疗慢性高原病的疗效与安全性。方法计算机检索PubMed、EMbase、CoChcrane Library、中国知网(CNKI)、万方数据库、维普等数据库,检索时限为建库至2019年12月。收集相关ACZ治疗慢性高原病的随机对照试验(RCTs)文献,根据Cocharane偏倚风险评价工具对纳入文献进行质量评价,设计数据提取表,数据提取、转化、核查、修改。采用Review Manager 5.3软件对数据进行Meta分析。结果初步检索获得文献301篇(英文294篇,中文7篇),经过EndNote软件去除重复文献113篇,通过阅读文题和摘要排除不符合纳入标准的文献161篇,经过阅读全文、剔除数据不全文献,最终纳入4篇文献(英文4篇,中文0篇),纳入的总样本数147例,其中实验组82例,对照组65例。Meta分析结果显示:ACZ 250 mg治疗慢性高原病,可以降低HCT(mean difference=-2.91;95%CI:-4.55^-1.28;P<0.001)、降低PCO2(mean difference=-4.60;95%CI:-5.88^-3.33;P<0.001)、升高PO2(mean difference=2.39;95%CI:0.99~3.80;P<0.001),与安慰剂组比较差异有统计学意义;降低CMS评分,但与安慰剂组比较差异无统计学意义(mean difference=-0.27;95%CI:-2.52~1.99;P>0.05)。ACZ 250 mg与ACZ 500 mg治疗慢性高原病均可提升PO2、降低PCO2,但两者比较差异无统计学意义(mean difference=-0.41;95%CI:-2.75~1.94;P>0.05)。ACZ治疗慢性高原病过程中不良反应轻微。结论 ACZ 250 mg治疗慢性高原病能降低红细胞数量,提高氧合,疗效明显;ACZ 250 mg与ACZ 500 mg治疗慢性高原病,疗效无差异;ACZ治疗慢性高原病不良反应少,安全可靠。